The Supreme Court Just Made Your Roundup Case Harder — But It Did Not Make It Impossible
You are reading this because you used Roundup. Maybe for years. Maybe on a farm, maybe on a grounds crew, maybe on your own driveway every summer. And then the diagnosis came back: non-Hodgkin’s lymphoma. A cancer of the lymphatic system that changes everything — the treatment schedule, the fear your family lives with, the income that stops while you sit in a chemotherapy chair.
And now you are hearing that the Supreme Court just ruled in a case called Monsanto v. Durnell, and the headline says it “unwinds corporate accountability for pesticides.” Your first thought is probably the one every person in your position has: Does this mean I can’t sue?
We are Attorney911 — The Manginello Law Firm. We handle toxic tort cases and the catastrophic injuries they cause, and we are writing this page for one reason: to give you an honest, straight answer about what this ruling means for your specific situation. Not a sales pitch. Not false hope. The truth about what survived, what did not, and what you need to do right now to protect whatever rights you still have.
Here is the short version: the ruling is a setback. It narrows the legal road. But it does not pave over every claim. Whether yours survives depends on factors we can only assess by looking at your actual case — your exposure history, your state of residence, the specific legal theories available to you, and how strong your medical and exposure documentation is. A person who sprayed glyphosate five times in their backyard and a person who mixed and applied it forty hours a week for a decade are in very different positions after this ruling. A person in a state with strong consumer-protection statutes and a person in a state with aggressive tort reform are in very different positions.
What we can tell you with certainty is this: the worst thing you can do right now is assume the ruling killed your case and walk away. The second worst thing you can do is wait. Toxic-tort claim deadlines typically run from the date of diagnosis or the date you discovered the connection between your illness and glyphosate — and the evidence that proves your exposure is dying on a clock that does not care about the Supreme Court.
Call us at 1-888-ATTY-911. The consultation is free. We do not get paid unless we win your case. And we will tell you honestly whether your claim is one that survived the ruling or one that did not.
What Monsanto v. Durnell Actually Did to Your Claim
The Supreme Court’s ruling in Monsanto v. Durnell addressed the single most important legal question in the entire Roundup litigation: whether federal pesticide law overrides state lawsuits that claim Monsanto should have warned users about cancer risks.
Federal pesticide regulation operates under the Federal Insecticide, Fungicide, and Rodenticate Act — FIFRA. Under FIFRA, the EPA reviews and approves the labeling for every pesticide sold in the United States. The EPA approved Roundup’s label. That label did not include a cancer warning. The EPA has historically maintained that glyphosate is “not likely to be carcinogenic to humans.”
The EPA has historically maintained that glyphosate is ‘not likely to be carcinogenic to humans,’ a position that directly conflicts with the 2015 International Agency for Research on Cancer classification of glyphosate as ‘probably carcinogenic to humans’ — creating the scientific-regulatory tension at the heart of the litigation.
Monsanto’s argument — the one that reached the Supreme Court in Durnell — was straightforward: if the federal government approved our label and did not require a cancer warning, then state courts cannot hold us liable for failing to add one. Federal law, Monsanto argued, preempts state tort law on the warning question.
The Supreme Court’s ruling shifted the landscape toward Monsanto’s position. That does not mean every claim is dead. But it means the theory that carried the most Roundup cases to trial — failure to warn — is the theory most vulnerable to being preempted. And that changes the strategic map of every glyphosate cancer claim in the country.
The Theory Most at Risk: Failure to Warn
For years, the backbone of Roundup litigation was a simple argument: Monsanto knew or should have known that glyphosate was linked to cancer, and it failed to put a warning on the label. The 2015 IARC classification — the world’s leading cancer research agency calling glyphosate “probably carcinogenic to humans” — was the scientific anchor. The internal documents showing Monsanto’s own scientists raised concerns were the proof.
If FIFRA preemption now shields EPA-approved labeling from state-law warning claims, that entire theory may be foreclosed in many jurisdictions. The argument that “the EPA said the label was fine” becomes a federal shield against the state-law duty to warn. That is the “unwinding” the headline describes.
The Theories That May Still Stand
But failure to warn is not the only theory. The dossier of liability against Monsanto includes several others, and their survival after the ruling varies:
Design defect. The argument that Roundup was defectively designed because its active ingredient, glyphosate, is linked to carcinogenic outcomes — and that safer alternative formulations could have reduced the cancer risk without sacrificing herbicidal efficacy. This theory attacks the product itself, not the label, and may sit outside FIFRA’s preemption scope. Whether it survives depends on how broadly the Court’s preemption reasoning extends.
Negligence. The argument that Monsanto breached its duty of reasonable care by marketing a product linked to fatal disease without sufficient warning or safety measures, despite internal and scientific awareness of carcinogenic risk signals. Negligence is a broader theory than failure to warn — it reaches the company’s conduct, not just the label it printed.
Strict liability — unreasonably dangerous product. The argument that Roundup is unreasonably dangerous as designed and marketed. This theory’s availability post-ruling must be assessed case by case, because some courts may read the preemption reasoning to reach beyond labeling into the broader product-liability frame.
Punitive damages. If discovery reveals Monsanto possessed internal knowledge of glyphosate’s carcinogenic potential and suppressed or manipulated scientific evidence, punitive damages may be available — subject to the ruling’s scope, applicable state punitive-damage standards, and any constitutional caps under state law. But punitive damages typically ride on top of an underlying liability theory. If the underlying theory is preempted, the punitive claim may fall with it.
The point is this: the ruling narrowed the road, but it did not close every lane. Which lane your case occupies is a question that demands a case-specific legal analysis — not a headline, not a Google search, and not a conclusion reached at 2 a.m. by a person in crisis.
The Science War Behind Every Glyphosate Case
Every glyphosate cancer claim lives inside a contradiction that the Supreme Court ruling did not resolve and cannot resolve: two respected scientific bodies looked at the same chemical and reached opposite conclusions.
The EPA says glyphosate is “not likely to be carcinogenic to humans.” The International Agency for Research on Cancer — IARC, the cancer agency of the World Health Organization — classified glyphosate as “probably carcinogenic to humans” in 2015. Both cannot be right. And the resolution of that contradiction is not a legal question; it is a scientific one that the Supreme Court’s preemption ruling did not settle.
What the ruling did was give Monsanto a procedural advantage: it lets the company point to the EPA’s approval and say, in effect, “the federal government said our label was adequate.” It does not change what IARC found. It does not erase the internal Monsanto documents that prior litigation surfaced. It does not alter the epidemiological studies that connect glyphosate exposure to elevated non-Hodgkin’s lymphoma risk.
What this means for your case is that the science still matters — enormously. The toxicologist who can explain the mechanism by which glyphosate damages human lymphocytes. The epidemiologist who can testify about the dose-response relationship between glyphosate exposure and NHL incidence. The oncologist who can connect your specific exposure history to your specific cancer. These experts are the backbone of every surviving glyphosate claim, and their work is not preempted by a labeling ruling.
The defense will try to use the ruling as a shield against the science too. They will argue that if the EPA found no carcinogenic risk, then state courts should not hear scientific evidence contradicting that finding. That argument overreaches — but you should expect it, and your legal team needs to be ready to defeat it.
Monsanto and Bayer: Who You Are Really Fighting
When you file a claim over glyphosate exposure, the defendant on the other side is not a small company. It is one of the largest pharmaceutical and chemical conglomerates on earth.
Monsanto Company manufactured Roundup and the entire line of glyphosate-based herbicides that are the subject of this litigation. In 2018, Bayer AG acquired Monsanto for $63 billion — creating a corporate parent with consolidated financial responsibility for Monsanto’s product-liability exposure. Bayer is a German multinational with deep pockets, a global legal apparatus, and every incentive to fight every claim as hard as it can.
Why does Bayer fight so hard? Because the exposure is not one case — it is tens of thousands. The federal multidistrict litigation, MDL-2741 in the Northern District of California before Judge Vince Chhabria, has been the central clearinghouse for Roundup cases nationwide. Bayer has already engaged in multi-billion-dollar settlement frameworks for prior Roundup litigation, and the Durnell ruling gives the company a powerful new tool to resist future claims.
But Bayer’s deep resources are also why strong-exposure cases with clear diagnostic timelines still carry leverage. A company that has paid billions before can pay again — if the case in front of it is strong enough and the legal theory is one that survived the ruling.
The Chain of Distribution
Beyond Monsanto and Bayer, entities in the chain of distribution of glyphosate products — distributors and retailers — may face strict product-liability claims under state law. The availability of these claims depends on the Supreme Court ruling’s preemption scope and state-specific distribution-liability rules. In some states, a retailer who sold a defective product can be held liable even if the manufacturer is shielded by federal preemption. In others, the chain is broken. This is a state-specific question that requires case-specific analysis.
The point is that naming every potentially liable entity in the chain — not just Monsanto — is part of how a plaintiff firm maximizes recovery in a post-Durnell world. If the manufacturer is shielded, the distributor may not be. If the primary defendant has a preemption defense, a different defendant in the same chain may not.
Non-Hodgkin’s Lymphoma: The Injury and the Proof
The core injury in glyphosate mass-tort litigation is non-Hodgkin’s lymphoma — NHL. It is a cancer of the lymphatic system, which is part of the body’s immune defense. NHL begins in white blood cells called lymphocytes, when those cells develop abnormalities that cause them to multiply uncontrollably.
What NHL Does to a Body
The treatment regimens are aggressive. Depending on the subtype and stage, a patient may face chemotherapy regimens that stretch across months, immunotherapy drugs that harness the immune system to attack the cancer, radiation therapy that damages healthy tissue alongside the malignant cells, and — in the most serious cases — stem cell transplantation, a procedure that essentially destroys and rebuilds the patient’s blood-forming system.
Treatment costs often exceed hundreds of thousands of dollars per patient. A single course of rituximab plus chemotherapy — the standard regimen for many NHL subtypes — can run well into six figures. A stem cell transplant can push the total past a million dollars. And that is before the lost wages, the diminished earning capacity, and the ongoing oncological monitoring that extends for years after remission.
The Proof Problem: General and Specific Causation
Every toxic tort case requires two kinds of proof, and NHL cases are no exception:
General causation means proving that glyphosate can cause non-Hodgkin’s lymphoma in humans — at the population level. This is where the IARC classification, the epidemiological studies, and the toxicological mechanism evidence come in. The defense fights this hard, pointing to the EPA’s contrary position and to studies that found no association. Your experts — a toxicologist or epidemiologist — carry this burden.
Specific causation means proving that your NHL was caused by your glyphosate exposure — not by something else. This is where your exposure documentation becomes decisive. An industrial hygienist reconstructs your exposure dose — how much glyphosate you absorbed, over how many years, through what pathways (skin contact, inhalation during mixing and spraying). An oncologist then connects that dose to your specific diagnosis.
The defense will exploit every gap. They will argue your NHL was idiopathic — meaning it came from nowhere, or from something else. They will point to age, family history, other chemical exposures, immune conditions, or any other factor that could explain your cancer without pointing at glyphosate. The counter is a tight, documented exposure timeline married to a clean differential diagnosis that rules out alternatives and leaves glyphosate as the most likely cause.
When NHL Turns Fatal
Non-Hodgkin’s lymphoma is treatable but not always curable. Some subtypes are aggressive and refractory — meaning they do not respond to standard treatment. When the disease progresses despite chemotherapy, immunotherapy, and transplant, the case becomes a wrongful death claim. Survival and wrongful-death damages apply, with the specific damage split governed by the applicable state’s statute — confirm the current state rule for your jurisdiction.
What Your Case Is Worth After the Ruling
Case valuation in glyphosate litigation was always highly fact-dependent. The Supreme Court ruling introduces additional uncertainty that likely compresses the upper range and potentially eliminates or limits certain damage categories.
The lower range: $75,000 to $300,000. This applies to claims with limited exposure documentation, weaker specific-causation expert support, shorter exposure duration, or theories significantly narrowed by the ruling. If your only evidence of exposure is your own statement that you used Roundup occasionally, and your state’s failure-to-warn theory is preempted, your case may fall here.
The higher range: $1,500,000 to $10,000,000 or more. This applies to claims with strong occupational or prolonged residential exposure, a confirmed NHL diagnosis with a documented treatment course, robust general and specific causation expert testimony, viable state-law theories that survive the ruling, and evidence supporting punitive damages. A farmworker who mixed and sprayed glyphosate daily for fifteen years, has coworker corroboration, purchase records, and application logs, and was diagnosed with a treatable NHL subtype after a documented treatment course — that case sits at the top of this range or above.
What the ruling changed. Prior to Durnell, comparable Roundup and NHL cases had yielded substantial verdicts and settlement contributions within a multi-billion-dollar aggregate resolution framework. The new precedent may reduce trial leverage and settlement pressure, particularly for marginal-exposure claims. But NHL severity — a cancer diagnosis with treatment costs in the hundreds of thousands and lifelong consequences — and Bayer’s deep resources maintain pressure for strong-exposure cases with clear diagnostic timelines.
The honest framing is this: the ruling did not eliminate the possibility of significant recovery. It made the path to that recovery narrower and more selective. Cases that would have settled before may now need to be tried. Theories that would have carried may now need to be reframed. And the quality of your exposure documentation — the thing you control most directly — matters more than it ever did.
Past results depend on the facts of each case and do not guarantee future outcomes.
The Evidence Clock: What Exists and How Fast It Dies
Every toxic tort case is a race against evidence decay. The Supreme Court ruling did not change that. What it changed is which evidence matters most — with failure-to-warn theories potentially preempted, the proof that establishes design defect, negligence, and specific causation becomes the center of gravity, and that proof is perishable.
Medical Records — Durable but Must Be Collected Promptly
Your complete medical records documenting your NHL diagnosis are the foundation: pathology reports confirming the lymphoma subtype, treatment history showing the chemotherapy or immunotherapy regimen, imaging studies, and your prognosis. These records are generally durable — hospitals and oncology practices retain them for years. But you should collect them promptly to establish a complete treatment timeline and prevent gaps. A missing pathology report or a gap in treatment records creates an opening the defense will exploit.
Exposure History — This Is What Dies
The single most perishable evidence in your case is your exposure documentation: purchase receipts showing you bought Roundup, work records showing you applied glyphosate on the job, agricultural-use logs, witness statements from coworkers or family members who saw you use it, and application records from farms or facilities where you worked.
Receipts degrade. Memories fade. Witnesses relocate. This documentation should be collected within months, not years. Every month that passes, a coworker who could confirm you sprayed glyphosate every Monday morning for a decade becomes harder to find. A receipt from 2015 becomes harder to locate. The exposure history you can document today will be weaker tomorrow — and weaker still next year.
Monsanto and Bayer Internal Documents
Internal corporate documents — scientific studies, risk assessments, marketing strategies, regulatory submissions, and allegations of ghostwriting in the scientific literature — support failure-to-warn, design-defect, and punitive-damages theories by showing what the manufacturer knew about carcinogenic risk and when. These documents are primarily accessible through coordinated mass-tort discovery. A firm aligned with active or prior MDL proceedings can access discovery that a firm working in isolation cannot.
EPA Registration Files and IARC Monograph
EPA registration files, FIFRA labeling submissions, the IARC monograph classifying glyphosate as probably carcinogenic, and regulatory correspondence between Monsanto and the EPA are public documents that establish the regulatory framework, the scientific controversy, and the preemption landscape. These are generally preserved as public records, but they should be cited to the specific versions and registrations in effect during your exposure period — pesticide registrations change over time.
Expert Witness Analyses
Expert witness opinions — toxicology, epidemiology, oncology, and industrial hygiene — bridge general causation and specific causation. Expert retention should occur early to meet discovery deadlines and to survive Daubert or Frye admissibility challenges under your state’s standard. The defense will challenge your experts aggressively, particularly after the ruling, arguing that the EPA’s contrary finding makes plaintiff causation testimony unreliable. Your experts need to be retained, prepared, and disclosed on a litigation schedule, not after the fact.
The Defense Playbook: What Bayer’s Lawyers Will Do
Bayer has one of the most sophisticated legal defense apparatuses in the world. The moves below are not speculation — they are the documented strategy of a company that has faced tens of thousands of Roundup claims and has refined its defense through years of litigation.
Play 1: “The EPA Approved Our Label — Federal Law Blocks Your Claim”
This is the Durnell play. Bayer will file a motion to dismiss or for summary judgment arguing that FIFRA preemption bars your state-law failure-to-warn claim because the EPA approved the Roundup label without requiring a cancer warning. After the Supreme Court ruling, this motion is stronger than it was before.
The counter: Preemption of failure-to-warn does not necessarily preempt every theory. If your case includes design-defect or negligence claims that attack the product’s formulation or the company’s conduct rather than the label, those claims may survive. The defense will try to stretch preemption to cover everything; your job is to plead theories that sit outside the preemption zone. This is where case-specific legal analysis by a trial attorney who understands the preemption map is not a luxury — it is the difference between a case that moves forward and one that is dismissed at the courthouse door.
Play 2: “Your Cancer Came from Somewhere Else”
The defense will argue that non-Hodgkin’s lymphoma has many causes — age, immune conditions, family history, other chemical exposures, viral infections — and that you cannot prove glyphosate caused yours. They will retain their own oncologist to testify that your NHL was idiopathic or attributable to a different risk factor.
The counter: A tight differential diagnosis by your own oncologist, combined with a dose reconstruction by an industrial hygienist, closes this gap. The defense’s “it could have been anything” argument loses force when your expert can show a documented, quantified exposure to a chemical that IARC classifies as probably carcinogenic, a latency period consistent with your diagnosis timeline, and the absence of competing risk factors in your medical history.
Play 3: “You Did Not Use Enough for Long Enough”
The defense will minimize your exposure. If you used Roundup on your garden, they will say it was too little to matter. If you used it for five years, they will say it was too short. They will challenge every estimate of frequency, duration, and intensity of use.
The counter: This is why exposure documentation is the most important thing you can preserve. Purchase receipts, work records, application logs, coworker statements — every document that shows how much you used and for how long directly answers this play. A person who can produce ten years of purchase records from a farm-supply store is in a fundamentally different position from a person who says “I used it sometimes.”
Play 4: “The Science Is Not Settled”
Bayer will attack your experts under Daubert or your state’s evidentiary standard, arguing that the epidemiological evidence linking glyphosate to NHL is too weak to support expert testimony. They will point to studies that found no association. They will argue the IARC classification is an outlier.
The counter: The IARC classification, the published epidemiological studies showing elevated NHL risk in highly exposed individuals, and the toxicological mechanism evidence form a scientific foundation that has survived Daubert challenges in prior Roundup trials. Your experts need to be prepared to defend their methodology and distinguish the studies the defense cites.
Play 5: Delay
Bayer’s lawyers know that evidence decays and that grieving families sometimes give up. They will file motions, request extensions, and push the timeline. Every month of delay is a month in which a witness becomes harder to reach, a receipt becomes harder to find, and a family’s resolve may weaken.
The counter: A firm that moves fast — sending preservation letters, demanding records, retaining experts, and pushing the case forward — denies the defense the delay advantage. The day you call is the day the clock starts working for you instead of against you.
How a Glyphosate Case Is Actually Built
Here is the chronological walk of a glyphosate cancer claim after Monsanto v. Durnell, from the first phone call through resolution:
Week one: ruling-impact analysis. The first thing a plaintiff firm must do is analyze which state-law theories survive the Supreme Court’s preemption framework. This threshold gate determines whether a case is fileable at all. If failure-to-warn is preempted in your state, does design defect survive? Does negligence? Does strict liability? The answer depends on your state’s preemption posture, its product-liability framework, and how broadly the Court’s reasoning extends. This is not a question a generalist can answer — and getting it wrong means filing a case that gets dismissed.
Weeks one through four: evidence preservation. The preservation letter goes out to Monsanto, to Bayer, to any downstream distributors, and to every entity that holds records of your exposure. Medical records are collected from every treating oncologist, every hospital, every imaging center. Exposure documentation is assembled — purchase receipts, employment records, agricultural-use logs, witness statements. The litigation hold freezes the evidence before it can disappear.
Months one through three: expert retention. A toxicologist or epidemiologist is retained for general causation — to testify that glyphosate causes NHL at the population level. An oncologist is retained for specific causation — to testify that your NHL was caused by your documented exposure. An industrial hygienist is retained to reconstruct and quantify your exposure dose — to translate “I used Roundup for years” into a defensible exposure estimate.
Months three through six: filing and discovery. The case is filed — strategically, in a state court that retains jurisdiction over non-preempted theories and offers favorable venue, jury pool, and damage-recovery profiles. Discovery demands go out for Monsanto and Bayer internal documents, accessible through coordinated mass-tort discovery infrastructure. Depositions are scheduled.
Months six through eighteen: depositions and motion practice. The defense files preemption motions. Your team responds. Expert depositions are taken — your experts and theirs. The defense’s experts are cross-examined on their methodology and their funding. Monsanto’s corporate witnesses are deposed on what they knew about glyphosate’s carcinogenic potential and when.
Mediation and settlement demands. Settlement demands must be recalibrated to the ruling’s impact. Diminished trial threat may require more realistic demand structures for marginal-exposure claims. But NHL severity and Bayer’s deep resources maintain pressure for strong-exposure cases with clear diagnostic timelines. A case that would have commanded a seven-figure settlement before Durnell may still command one — if the exposure is strong and the surviving theories are viable.
Trial. If settlement is not reached, the case goes to trial. Voir dire should explore juror attitudes toward chemical regulation, corporate-funded science, and the tension between EPA safety determinations and independent international scientific findings. The jury that decides your case needs to understand that the EPA’s “not likely carcinogenic” finding and IARC’s “probably carcinogenic” classification are two different agencies looking at the same chemical and reaching different conclusions — and that the jury is entitled to credit either one.
State-by-State: Where Your Claim May Still Live
Because Monsanto v. Durnell involves a federal Supreme Court ruling with nationwide preemption implications, no single state’s law controls. But state courts retain varying degrees of authority over product-liability claims depending on preemption analysis and state consumer-protection statutes.
States with strong consumer-protection statutes and anti-preemption provisions — including California under Proposition 65 and states with plaintiff-friendly venue precedent — may offer more resilient forums for surviving claims. California’s Proposition 65, for example, requires businesses to provide warnings about exposures to chemicals known to cause cancer, and California’s courts have historically been more receptive to plaintiff product-liability theories.
States with strong tort-reform provisions may further compress recoverable damages, regardless of whether the underlying theory survives preemption. Non-economic damage caps, punitive-damage caps, and heightened pleading standards can all reduce the value of an otherwise viable claim.
The specific state matters. Your state’s preemption posture, its product-liability framework, its treatment of design-defect and negligence claims in pesticide cases, its statute of limitations and discovery-rule formulation, and its damage-recovery profile all determine whether your claim is fileable and what it is worth. This is not a national one-size-fits-all answer. It is a state-specific legal question that requires analysis by a trial attorney who knows your state’s law.
If your claim involves a death from NHL, the wrongful death claim process adds another state-specific layer: who may file, what damages are recoverable, and what deadline applies.
Your First Steps: What to Do Now
If you used glyphosate-containing products and were diagnosed with non-Hodgkin’s lymphoma, here is what you should do — and what you should not do — in the days and weeks ahead.
Do gather your medical records. Your pathology report, your treatment history, your imaging studies, your prognosis — these are the foundation of your case. Contact every oncologist, hospital, and imaging center that has treated you and request complete copies of your records. You are entitled to them.
Do document your exposure history. Write down everything you can remember about your glyphosate use: what products you used, when you started, when you stopped, how often you used them, where you used them, whether you mixed concentrates, what protective equipment you wore, and who else was present. Find purchase receipts. Find employment records. Find anyone who can corroborate your exposure. This documentation is the most perishable evidence in your case — and the most important.
Do talk to a lawyer who handles toxic tort cases. Not a generalist. Not a friend who does wills and divorces. A trial attorney who understands FIFRA preemption, product-liability law, and the specific landscape of post-Durnell glyphosate litigation. The consultation should be free. The lawyer should be able to tell you, after reviewing your facts, whether your claim is one that survived the ruling and what it might be worth.
Do not sign anything from Monsanto, Bayer, or any insurance company. If you receive a letter, a release, a settlement offer, or a request for a recorded statement, do not respond without speaking to a lawyer first. These documents are designed to limit or extinguish your rights — and they arrive looking like routine paperwork.
Do not post about your case on social media. The defense will monitor your public profiles. A photograph of you doing something physical, a post about feeling well, a comment about your diagnosis — all of these can be taken out of context and used to minimize your injury.
Do not wait. Toxic-tort limitation periods typically run from the date of diagnosis or discovery of the causal link between your illness and the exposure. Delayed action could permanently extinguish viable claims regardless of the ruling’s scope. The statute of limitations in your state is a hard deadline — and in some states, a separate statute of repose can cut off your claim even before discovery. The only way to know the deadline that applies to you is to have a lawyer in your state confirm it.
Frequently Asked Questions
Can I still sue Monsanto after the Supreme Court’s Monsanto v. Durnell ruling?
It depends on your specific case. The ruling narrows the legal avenues available, particularly for failure-to-warn claims, but it does not automatically extinguish every claim. Design-defect, negligence, and strict-liability theories may survive in some states and under some factual patterns. Whether your specific claim survives requires a case-specific legal analysis by a trial attorney who understands the preemption landscape in your state.
How long do I have to file a glyphosate cancer claim?
The deadline varies by state. Toxic-tort limitation periods typically run from the date of diagnosis or the date you discovered — or should have discovered — the connection between your illness and glyphosate exposure. This is called the discovery rule. Some states also have a statute of repose that can cut off your claim even before discovery. You need a lawyer in your state to confirm the exact deadline that applies to your facts. Waiting is the single most common way viable claims die.
What if I used Roundup years ago — is it too late?
Not necessarily. The discovery rule means the clock often starts when you were diagnosed with non-Hodgkin’s lymphoma or when you learned that glyphosate could have caused it — not when you last used the product. Many people are diagnosed years or decades after their exposure ended. But every state’s rule is different, and some have outer deadlines that can bar a claim regardless of when you discovered the cause. The only safe move is to have the deadline confirmed for your specific state and facts.
Do I need to prove that Roundup specifically caused my cancer?
Yes. This is called specific causation, and it is one of the hardest parts of a glyphosate case. You need to prove that your non-Hodgkin’s lymphoma was caused by your exposure to glyphosate — not by age, genetics, or some other factor. This requires expert testimony from an oncologist and a toxicologist or industrial hygienist who can connect your documented exposure dose to your specific diagnosis. The defense will argue your cancer came from somewhere else. Your exposure documentation — how much you used, how often, for how long — is the evidence that defeats that argument.
What is my glyphosate cancer case worth?
Case values range widely. Claims with limited exposure documentation and weakened legal theories may fall in the $75,000 to $300,000 range. Claims with strong occupational or prolonged exposure, confirmed NHL diagnosis, robust expert testimony, and viable state-law theories may reach $1,500,000 to $10,000,000 or more. The Supreme Court ruling introduces uncertainty that likely compresses the upper range. The value of your specific case depends on your exposure strength, your state’s law, your diagnosis and treatment history, and whether punitive-damages evidence is available. Past results depend on the facts of each case and do not guarantee future outcomes.
What if my family member died from non-Hodgkin’s lymphoma after using Roundup?
You may have a wrongful-death claim, depending on your state’s law and your relationship to the deceased. Wrongful-death and survival actions carry their own damage categories and deadlines, governed by your state’s statute. If your loved one’s NHL was fatal and you believe glyphosate exposure was the cause, you should speak to a lawyer immediately — wrongful-death deadlines can be shorter than personal-injury deadlines in some states.
Will the EPA pause glyphosate use because of this ruling?
The article that brought this ruling to public attention is a call-to-action from a public-interest advocacy organization urging the EPA to suspend the use of glyphosate, citing its link to cancers including non-Hodgkin’s lymphoma. Whether the EPA takes that action is a regulatory question separate from your legal claim. Your right to sue does not depend on the EPA pausing glyphosate — it depends on whether your specific legal theories survive the Supreme Court’s preemption ruling and your state’s law.
How much does it cost to hire a lawyer for a glyphosate case?
Our firm works on contingency. That means you pay nothing upfront. We do not get paid unless we win your case. The consultation is free. If we take your case and recover compensation, our fee is a percentage of the recovery — 33.33% before trial and 40% if the case goes to trial. If we do not recover anything, you owe us nothing. This is not a promise of a result — it is a promise about how we get paid.
What should I bring to my first consultation with a lawyer?
Bring whatever you have: your pathology report and treatment records, any purchase receipts or employment records showing glyphosate use, a written timeline of when and how you used glyphosate-containing products, a list of witnesses who can corroborate your exposure, and any correspondence you have received from Monsanto, Bayer, or any insurance company. Do not worry if you do not have everything — a good lawyer will help you identify what is missing and how to get it.
Why Attorney911
We are Attorney911 — The Manginello Law Firm, PLLC. We have been in practice since July 18, 2001 — more than 24 years. Our managing partner, Ralph Manginello, has been licensed since November 6, 1998 — 27+ years in courtrooms, including federal court. He was a journalist before he was a lawyer, which means he knows how to find the story the evidence tells and how to tell it to a jury. He is admitted to the U.S. District Court for the Southern District of Texas and handles cases that demand a federal-court trial lawyer’s command of complex regulatory law — exactly what FIFRA preemption requires.
Lupe Peña is our associate attorney and a former insurance-defense attorney. He spent years inside a national defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how the other side values a case, how they pick their experts, how they structure their delays, and where their playbook crosses into bad faith. He now uses that knowledge for injured clients. And he conducts full consultations in Spanish — without an interpreter.
We handle cases on contingency. We do not get paid unless we win. The consultation is free. We have 24/7 live staff — not an answering service. When you call, a person answers.
We are not the counsel of record on the Monsanto v. Durnell case. We have not been retained by any party in that litigation. What we are is a trial firm that understands the preemption landscape this ruling created, the medicine of non-Hodgkin’s lymphoma, the evidence a glyphosate case demands, and the deadlines that kill claims quietly. If you are facing a situation like the one described on this page, we are a powerful resource — the education, the governing law, the evidence clocks, the honest evaluation of what a case like yours is worth.
The fight over glyphosate and cancer is not over. It is harder than it was before the Supreme Court ruled. But harder is not the same as impossible. If your exposure was real, your diagnosis is confirmed, and your state’s law offers a theory that survived, your case may be one of the ones that still moves forward.
The first step is a phone call. 1-888-ATTY-911. Free consultation. No fee unless we win.
Hablamos Español.
This page is legal information, not legal advice. Past results depend on the facts of each case and do not guarantee future outcomes. Contacting the firm is free and confidential. The firm works on contingency — 33.33% before trial, 40% if trial begins.